IP Verse

Maiwald competitive analysis

Explore patent oppositions filed by Maiwald against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Jul 16, 2026

Patent Number	Title	Applicant	Opposition Date
EP4037735	Drug Delivery Device	AMGEN	Jun 3, 2026
EP4385509	Migalastat Formulations Having Improved Pharmacokinetics	AMICUS THERAPEUTICS	Jun 1, 2026
EP4157291	Ophthalmic Composition Based On Hyaluronic Acid To Protect From Damages Caused By Environmental Pollution	COLOMBO	May 12, 2026
EP4186523	A Novel Method For Stabilization Of A Biopharmaceutical Drug Product During Processing	LEUKOCARE	May 5, 2026
EP4374918	Methods Of Treating Fabry Patients Having Renal Impairment	AMICUS THERAPEUTICS	Apr 15, 2026
EP3689365	Use Of Long-Acting Glp-1 Peptides	NOVO NORDISK	Apr 9, 2026
EP3908276	Methods Of Treating Conditions Related To The S1P1 Receptor	ARENA PHARMACEUTICALS	Mar 11, 2026
EP4061358	Methods Of Treating Conditions Related To The S1P1 Receptor	ARENA PHARMACEUTICALS	Feb 27, 2026
EP3745128	A Cell Mediated Immune Response Assay	CELLESTIS	Feb 20, 2026
EP3730126	Liquid Composition Comprising Vegf Antagonist	SAMSUNG BIOEPIS	Feb 12, 2026

Discover the latest PTAB cases involving Maiwald, highlighting their recent legal challenges and patent disputes.

IP litigation analysis comparing Maiwald with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Jul 16, 2026

Company	Oppositions Filed	Oppositions Faced	PTAB Cases Filed	PTAB Cases Faced
MAIWALD	151	-	-	-
AMGEN	9	145	8	11
F HOFFMANN LA ROCHE	16	195	-	-
NOVARTIS	6	472	-	21